24,000 Shares in Autolus Therapeutics PLC Sponsored ADR $AUTL Acquired by Delaney Dennis R

Delaney Dennis R bought a new position in shares of Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) in the 2nd quarter, Holdings Channel.com reports. The institutional investor bought 24,000 shares of the company’s stock, valued at approximately $55,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. Knott David M Jr bought a new position in shares of Autolus Therapeutics during the 1st quarter worth approximately $651,000. Armistice Capital LLC lifted its position in shares of Autolus Therapeutics by 19.6% during the 1st quarter. Armistice Capital LLC now owns 11,000,000 shares of the company’s stock worth $17,050,000 after buying an additional 1,800,000 shares during the period. Atle Fund Management AB lifted its position in shares of Autolus Therapeutics by 130.5% during the 2nd quarter. Atle Fund Management AB now owns 1,105,461 shares of the company’s stock worth $2,520,000 after buying an additional 625,817 shares during the period. Cetera Investment Advisers lifted its position in shares of Autolus Therapeutics by 47.3% during the 1st quarter. Cetera Investment Advisers now owns 524,872 shares of the company’s stock worth $814,000 after buying an additional 168,650 shares during the period. Finally, Exchange Traded Concepts LLC lifted its position in shares of Autolus Therapeutics by 67.2% during the 1st quarter. Exchange Traded Concepts LLC now owns 69,993 shares of the company’s stock worth $108,000 after buying an additional 28,127 shares during the period. Institutional investors own 72.83% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the company. William Blair restated an “outperform” rating on shares of Autolus Therapeutics in a research report on Wednesday, September 24th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Autolus Therapeutics in a report on Wednesday, October 8th. Wells Fargo & Company reduced their price objective on Autolus Therapeutics from $6.00 to $5.00 and set an “overweight” rating on the stock in a research note on Wednesday, August 13th. Wall Street Zen upgraded Autolus Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 16th. Finally, Needham & Company LLC restated a “buy” rating and set a $10.00 target price on shares of Autolus Therapeutics in a report on Monday, July 21st. Six investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $9.12.

Autolus Therapeutics Stock Performance

NASDAQ AUTL opened at $1.66 on Monday. The stock has a fifty day moving average of $1.66 and a 200-day moving average of $1.78. The stock has a market capitalization of $441.79 million, a P/E ratio of -1.98 and a beta of 1.84. Autolus Therapeutics PLC Sponsored ADR has a 52 week low of $1.11 and a 52 week high of $5.00.

Autolus Therapeutics (NASDAQ:AUTL) last released its earnings results on Tuesday, August 12th. The company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.24) by $0.06. The firm had revenue of $13.50 million during the quarter, compared to analyst estimates of $12.92 million. Equities research analysts forecast that Autolus Therapeutics PLC Sponsored ADR will post -0.94 earnings per share for the current fiscal year.

Autolus Therapeutics Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.